About
Treatments for autoimmune diseases and inflammation
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyChina
Clinical Trials (21)
View allTotal Trials
21
As Lead Sponsor
21
As Collaborator
0
Total Enrollment
2,806
By Phase
PHASE1: 11PHASE2: 9PHASE3: 1
By Status
COMPLETED: 9RECRUITING: 6NOT_YET_RECRUITING: 3ACTIVE_NOT_RECRUITING: 1WITHDRAWN: 1TERMINATED: 1
Clinical Trials Pipeline21 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT04933422Lead Sponsor
CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
PHASE1Not yet recruiting
72 participants
Started: Jan 31, 2027 · Completed: Jul 31, 2029
NCT07169552Lead Sponsor
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
PHASE2Not yet recruiting
50 participants
Started: Sep 15, 2025 · Completed: Sep 30, 2027
NCT07057349Lead Sponsor
CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
PHASE1Not yet recruiting
40 participants
Started: Sep 1, 2025 · Completed: Feb 28, 2029
NCT06940154Lead Sponsor
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
PHASE2Recruiting
160 participants
Started: Aug 12, 2025 · Completed: May 31, 2026
NCT06940141Lead Sponsor
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
PHASE2Recruiting
160 participants
Started: Aug 8, 2025 · Completed: May 31, 2026
Locations (1)
Headquarters
Jiangsu, China
Map
Loading map...